Navigation Links
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Date:8/2/2009

al funding, if needed, to support its business activities. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law.

    Contacts:

    Purdue Pharma L.P.                 Transcept Pharmaceuticals, Inc.
    James Heins                        Greg Mann
    Senior Director, Public Affairs    Director of Corporate Communications
    (203) 588-8069                     (510) 215-3567
    james.heins@pharma.com             gmann@transcept.com

    Libby Holman                       The Ruth Group
    Associate Director, Public Affairs Investors / Media
    (203) 588-7670                     Sara Ephraim Pellegrino / Jason Rando
    libby.holman@pharma.com            (646) 536-7017 / 7025
                                       spellegrino@theruthgroup.com
                                       jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.; Purdue Pharmaceutical Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Purdue creating wireless sensors to monitor bearings in jet engines
2. Purdue leads center to simulate behavior of micro-electromechanical systems
3. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
4. Purdue researcher invents molecule that stops SARS
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 AstraZeneca (NYSE: ... Virginia (UVa) in Charlottesville, today announced that ... collaboration to enhance development of new treatments ... a secondary focus on peripheral vascular disease ... ,, The collaborative preclinical research projects will ...
(Date:12/15/2009)... PHILADELPHIA, Dec. 15 The Center ... Advanstar Communications, is pleased to announce the ... Pharmaceutical/Biotech Accounting and Reporting Congress . The ... Philadelphia, on March 16-17, 2010. ,, Over ... professionals have attended this premier event since ...
(Date:12/15/2009)... the launch of several innovative new programs to aid ... current economic climate. The first is aimed at ... services over a period of 6, 12, 18, or ... companies. The second is aimed at more established ... 6 to 12 month period at discounted rates, and ...
(Date:12/14/2009)... Patrick Kennedy Joins with State Biotech Leaders ... in Research and Development while Boosting Rhode ... ,, PROVIDENCE, R.I., Dec. 14 /PRNewswire-USNewswire/ ... leaders in research, medicine and biotechnology gathered ... to discuss the importance of medical innovation ...
Breaking Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4
... Association for Cancer Research ... ... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announced that it presented ... at the 2008 American Association for Cancer Research (AACR),Annual Meeting. ...
... BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, April 15, THIS ... INVESTORS SHOULD NOT SUBSCRIBE FOR OR PURCHASE ANY,SECURITIES ... BASIS OF,INFORMATION TO BE CONTAINED IN THE PROSPECTUS ... WITH THE PROPOSED SCHEME. THE PROSPECTUS WILL,BE PUBLISHED ...
... Symmetry Medical Inc.,(NYSE: SMA ), a leading ... and other medical markets, today announced that,the filing of ... Securities and,Exchange Commission will be delayed beyond its previously ... the final stages and the work is,substantially completed. The ...
Other Biology Technology:ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 2ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 4ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 5Shire to Introduce a New UK Listed Holding Company 2Shire to Introduce a New UK Listed Holding Company 3Shire to Introduce a New UK Listed Holding Company 4Shire to Introduce a New UK Listed Holding Company 5Shire to Introduce a New UK Listed Holding Company 6Shire to Introduce a New UK Listed Holding Company 7Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target 2Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target 3
(Date:12/15/2009)... . , Leipzig: Species distribution models are of ... mammals. This is the finding of a study of ... researchers analysed data on species distribution, climate, land cover ... the species. Judging by the large differences in climate ... adapt fast to changing climatic conditions. This in turn ...
(Date:12/15/2009)... a standard laboratory model organism, but there are ... analyze blood and blood-forming tissues in this species. ... easy-to-use laboratory resources from Cold Spring Harbor Laboratory ... features step-by-step protocols for the preparation, enumeration, ... and other hematopoietic tissues in the mouse. ...
(Date:12/14/2009)... 2009) -- Researchers at Rice University and Baylor College ... can be tracked in real time with MRI as ... a fluorescent dye and kills them with heat. The ... a growing field called "theranostics" that develops technologies physicians ... single procedure. , The research is available online in ...
Breaking Biology News(10 mins):Species distribution models are of only limited value for predicting future mammal distributions 2New source of classical techniques for blood-based studies in the laboratory mouse 2Tracking new cancer-killing particles with MRI 2MedAppz Signs Agreement with MedAssets to Offer SAAS based Electronic Health Record to MedAssets 26apos 3B Non acute Customers 60045 1MedAppz Signs Agreement with MedAssets to Offer SAAS based Electronic Health Record to MedAssets 26apos 3B Non acute Customers 60045 2Cardiac Patients Across Rural America Risk Losing Access to Nearby Care as Federal Agency Considers Cuts this Week 60042 1Cardiac Patients Across Rural America Risk Losing Access to Nearby Care as Federal Agency Considers Cuts this Week 60042 2Cardiac Patients Across Rural America Risk Losing Access to Nearby Care as Federal Agency Considers Cuts this Week 60042 3Novo Nordisk Wins Design Award for NovoTwist 28TM 29 Needle 5671 1Novo Nordisk Wins Design Award for NovoTwist 28TM 29 Needle 5671 2Novo Nordisk Wins Design Award for NovoTwist 28TM 29 Needle 5671 3
... -- Stress may indeed be a direct contributor to ... University study finding that increased levels of stress in ... being overweight or obese. , The study of 1,011 ... families living in three cities -- Boston, Chicago and ...
... gallery for Princeton University,s third Art of Science competition will ... site that allows members of the public to choose their ... the same time. , The juried show features 48 works ... can be found here: , www.princeton.edu/artofscience/2009 , The ...
... can provide an early advantage to the chicks that ... extra-pair offspring). , It has long been known ... their social partner, producing broods of mixed paternity in ... half brothers and sisters. , While the superiority ...
Other Biology News:Study finds link between individual stress and adolescent obesity 2Study finds link between individual stress and adolescent obesity 3Exhibition showcases the 'art of science' 2Exhibition showcases the 'art of science' 3Mothers give interloper's offspring a head start in life 2Mothers give interloper's offspring a head start in life 3
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
... The new Finnpipette Focus ... tip cone for pipetting from ... other narrow and long necked ... that whatever volume you select, ...
Biology Products: